133 related articles for article (PubMed ID: 6213066)
1. Thrombin potentiation of factor VIII procoagulant activity: assessment by the two-stage assay.
Kopitsky RG; Switzer ME; McKee PA
Thromb Haemost; 1982 Apr; 47(2):145-9. PubMed ID: 6213066
[TBL] [Abstract][Full Text] [Related]
2. Some effects of calcium on the activation of human factor VIII/Von Willebrand factor protein by thrombin.
Switzer ME; McKee PA
J Clin Invest; 1977 Oct; 60(4):819-28. PubMed ID: 408379
[TBL] [Abstract][Full Text] [Related]
3. The basis for the increase in factor VIII procoagulant activity during exercise.
Kopitsky RG; Switzer ME; Williams RS; McKee PA
Thromb Haemost; 1983 Feb; 49(1):53-7. PubMed ID: 6405498
[TBL] [Abstract][Full Text] [Related]
4. Characterisation of an antibody specific for coagulation factor VIII that enhances factor VIII activity.
Takeyama M; Nogami K; Matsumoto T; Soeda T; Suzuki T; Hattori K; Shima M
Thromb Haemost; 2010 Jan; 103(1):94-102. PubMed ID: 20062922
[TBL] [Abstract][Full Text] [Related]
5. Plasmin-induced procoagulant effects in the blood coagulation: a crucial role of coagulation factors V and VIII.
Ogiwara K; Nogami K; Nishiya K; Shima M
Blood Coagul Fibrinolysis; 2010 Sep; 21(6):568-76. PubMed ID: 20625277
[TBL] [Abstract][Full Text] [Related]
6. Kinetic parameters of monoclonal antibodies ESH2, ESH4, ESH5, and ESH8 on coagulation factor VIII and their influence on factor VIII activity.
Egler C; Albert T; Brokemper O; Zabe-Kühn M; Mayer G; Oldenburg J; Schwaab R
J Mol Recognit; 2009; 22(4):301-6. PubMed ID: 19266540
[TBL] [Abstract][Full Text] [Related]
7. Immunologic studies of native and modified human factor VIII/von Willebrand factor.
Switzer ME; McKee PA
Blood; 1979 Aug; 54(2):310-21. PubMed ID: 88237
[TBL] [Abstract][Full Text] [Related]
8. Role of the B domain in proteolytic inactivation of activated coagulation factor VIII by activated protein C and activated factor X.
Khrenov AV; Ananyeva NM; Saenko EL
Blood Coagul Fibrinolysis; 2006 Jul; 17(5):379-88. PubMed ID: 16788314
[TBL] [Abstract][Full Text] [Related]
9. Effects of anti-factor VIII inhibitor antibodies on factor VIIa/tissue factor-catalysed activation and inactivation of factor VIII.
Yada K; Nogami K; Ogiwara K; Shibata M; Shima M
Thromb Haemost; 2011 Jun; 105(6):989-98. PubMed ID: 21437361
[TBL] [Abstract][Full Text] [Related]
10. In vitro kinetics of factor VIII activity in patients with mild haemophilia A and a discrepancy between one-stage and two-stage factor VIII assay results.
Rodgers SE; Duncan EM; Barbulescu DM; Quinn DM; Lloyd JV
Br J Haematol; 2007 Jan; 136(1):138-45. PubMed ID: 17222201
[TBL] [Abstract][Full Text] [Related]
11. The physical exchange of factor VIII (FVIII) between von Willebrand factor and activated platelets and the effect of the FVIII B-domain on platelet binding.
Li X; Gabriel DA
Biochemistry; 1997 Sep; 36(35):10760-7. PubMed ID: 9271507
[TBL] [Abstract][Full Text] [Related]
12. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients.
Deitcher SR; Tuller J; Johnson JA
Haemophilia; 1999 Mar; 5(2):88-95. PubMed ID: 10215955
[TBL] [Abstract][Full Text] [Related]
13. Induction of human factor VIII inhibitors in rats by immunization with human recombinant factor VIII: a small animal model for humans with high responder inhibitor phenotype.
Jarvis MA; Levin LG; Harrison JA; DePianto DJ; Suzuki CM; Ziaja CL; Brown JE; Jolly KW; Reisner HM; Abildgaard CF; Powell JS
Thromb Haemost; 1996 Feb; 75(2):318-25. PubMed ID: 8815584
[TBL] [Abstract][Full Text] [Related]
14. Impaired prothrombin consumption in Bernard-Soulier syndrome is corrected in vitro by human factor VIII.
Bellucci S; Girma JP; Lozano M; Meyer D; Caen JP
Thromb Haemost; 1997 Feb; 77(2):383-6. PubMed ID: 9157600
[TBL] [Abstract][Full Text] [Related]
15. Assessment of bleeding for the evaluation of therapeutic preparations in small animal models of antibody-induced hemophilia and von Willebrand disease.
Turecek PL; Gritsch H; Richter G; Auer W; Pichler L; Schwarz HP
Thromb Haemost; 1997 Mar; 77(3):591-9. PubMed ID: 9066015
[TBL] [Abstract][Full Text] [Related]
16. Thrombin generation in haemophilia A patients with mutations causing factor VIII assay discrepancy.
Gilmore R; Harmon S; Gannon C; Byrne M; O'Donnell JS; Jenkins PV
Haemophilia; 2010 Jul; 16(4):671-4. PubMed ID: 20148980
[TBL] [Abstract][Full Text] [Related]
17. Recombinant factor VIII and factor VIII-von Willebrand factor complex do not present danger signals for human dendritic cells.
Pfistershammer K; Stöckl J; Siekmann J; Turecek PL; Schwarz HP; Reipert BM
Thromb Haemost; 2006 Sep; 96(3):309-16. PubMed ID: 16953272
[TBL] [Abstract][Full Text] [Related]
18. Standardisation of factor VIII and von Willebrand factor in plasma: calibration of the 4th International Standard (97/586).
Hubbard AR; Rigsby P; Barrowcliffe TW
Thromb Haemost; 2001 Apr; 85(4):634-8. PubMed ID: 11341497
[TBL] [Abstract][Full Text] [Related]
19. A solvent/detergent-treated and 15-nm filtered factor VIII: a new safety standard for plasma-derived coagulation factor concentrates.
Chtourou S; Porte P; Nogré M; Bihoreau N; Cheesman E; Samor B; Sauger A; Raut S; Mazurier C
Vox Sang; 2007 May; 92(4):327-37. PubMed ID: 17456157
[TBL] [Abstract][Full Text] [Related]
20. The factor VIII/von Willebrand factor complex: basic and clinical issues.
Federici AB
Haematologica; 2003 Jun; 88(6):EREP02. PubMed ID: 12826528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
